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Abstract 
Cationic liposomes may be valuable for the delivery of anti-sense oligonucleotides, ribozymes, and therapeutic genes into human 
immunodeficiency virus type 1 (HIV-1)-infected and uninfected cells. We evaluated the toxicity of three cationic liposomal preparations, 
Lipofectamine, Lipofectin, and 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE) reagent, o HIV-infected 
and uninfected cells. Monocyte/macrophages w re infected with HIV-1BaL and treated with liposomes in medium containing 20% fetal 
bovine serum (FBS) for 4 h or 24 h at 37°C. Uninfected monocytic THP-1 cells and chronically infected THP-1/HIV-ImB cells were 
treated with phorbol 12-myristate 13-acetate (PMA) and exposed to liposomes in the presence of 10% FBS. Toxicity was evaluated by the 
Alamar Blue assay and viral p24 production. The toxic effect of cationic liposomes was very limited with uninfected cells, although 
concentrations of liposomes that were not toxic within a few days of treatment could cause toxicity at later times. In HIV-I Bae-infected 
macrophages, Lipofectamine (up to 8 ~M) and Lipofectin (up to 40 txM) were not toxic after a 4-h treatment, while DMRIE reagent at 
40 txM was toxic. While a 4-h treatment of THP-1/HIV-lum cells with the cationic liposomes was not toxic, even up to 14 days 
post-treatment, all three cationic liposomes were toxic to cells at the highest concentration tested after a 24-h treatment. Similar results 
were obtained with the Alamar Blue assay, Trypan Blue exclusion and a method that enumerates nuclei. Infected cells with relatively high 
overall viability could be impaired in their ability to produce virions, indicating that virus production appears to be more sensitive to 
treatment with the cationic liposomes than cell viability. Our results indicate that HIV-infected cells are more susceptible than uninfected 
cells to killing by cationic liposomes. The molecular basis of this differential effect is unknown; it is proposed that alterations in cellular 
membranes during virus budding cause enhanced interactions between cationic liposomes and cellular membranes. 
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1. Introduction 
Cationic liposomes provide a simple and efficient means 
of introducing DNA and other polynucleotides into eukary- 
otic cells. Small unilamellar l iposomes composed of 
cationic lipids spontaneously complex with negatively 
charged compounds. In most cases transfection becomes 
efficient only when liposomes contain the membrane fu- 
sion-promoting lipid, dioleoylphosphatidylethanolamine 
(DOPE), and the nucleic acid-lipid complexes have a net 
positive charge [1,2]. Cationic liposomes have been used to 
facilitate delivery of DNA [3-7], mRNA [8], antisense 
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oligonucleotides [9] and proteins [10,11] into living cells. 
Unlike viral vectors, l iposomes are noninfectious and ap- 
pear to be non-immunogenic in vivo. They have been 
utilized for gene delivery in vivo [1,12-15], and a direct 
gene transfer protocol using a l iposome-DNA complex has 
been approved for injection into solid tumors in patients 
[16]. 
Although many studies have been carried out to im- 
prove l iposome-mediated transfection (lipofection), these 
techniques uffer from variable transfection efficiency. The 
composition of the cationic liposomes, the l ipid-DNA ra- 
tio, overall lipid concentration, the cell type and the den- 
sity of the cell culture are critical for efficient ransfection 
[2,3,17]. Since the first report of transfection by the cationic 
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lipid reagent, Lipofectin [3], several different kinds of 
cationic lipids have been developed, including quaternary 
ammonium detergents, cationic derivatives of cholesterol 
and diacyl glycerol, and lipid derivatives of polyamines 
[1,181. 
Cationic liposomes and DNA-liposome complexes may 
enter the cells by membrane fusion or spontaneous endocy- 
tosis, but the precise mechanism of their interaction with 
the cell membrane has not been elucidated. Liposomes 
composed of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimeth- 
ylammonium (DOTMA), the cationic component of Lipo- 
fectin, were found to undergo lipid mixing with lympho- 
cytic A3.01 and Raji cells in serum-free medium. How- 
ever, lipid mixing was inhibited by the presence of serum, 
although the liposomes could still bind to the cell mem- 
brane [19]. Cationic liposomes can undergo fusion with 
negatively charged liposomes and erythrocyte membranes 
[4,20,21]. The diffuse pattern of fluorescence in cell mem- 
branes following incubation with DNA-complexed 
DOTMA/DOPE liposomes has been interpreted as reflect- 
ing the fusion of the lipid DNA complex with the plasma 
membrane of the cells, resulting in delivery of the exoge- 
nous DNA into the cytoplasm [3,4]. On the other hand, the 
fusion activity of certain cationic liposomes (measured by 
their ability to fuse with negatively charged liposomes) can 
be abolished by preincubation with DNA; nevertheless, 
these lipids can mediate efficient uptake of DNA by 
cultured cells [22]. In addition, the fusion activities of 
different cationic liposomes, in the absence or presence of 
DNA, do not correlate with their transfection activities 
[22]. It is possible that the majority of DNA-liposome 
complexes are taken up through adsorption-mediated en o- 
cytosis. Although a recent study has indicated that the 
fusion of cationic liposomes with cultured Hep G-2 cells in 
phosphate-buffered saline occurs following endocytosis 
[23], it is not known whether DNA-liposome complexes 
can also undergo fusion after endocytosis, and what the 
effect of serum is on this process. Since fusion of the 
endocytotic vesicles with lysosomes would lead to degra- 
dation of the DNA, the DNA must enter the cytoplasm 
before this fusion event for successful transfection to 
occur. The endosome membrane may be destabilized by 
the cationic lipid,resulting in the release of the intact 
DNA-liposome complex into the cytoplasm [22-26]. Very 
little is known about the mechanism by which DNA 
localizes in the nucleus, except hat only a small percent- 
age of the cytoplasmically delivered DNA reaches the 
nucleoplasm [4,27]. It is possible that the cationic lipo- 
some-DNA complex enters the nucleus as an intact com- 
plex [28]. Lipofectin complexes of antisense oligonucleo- 
tides also localize in the nucleus, as well as in discrete 
structures in the cytoplasm [29]. 
Cells of monocyte/macrophage lin age can be easily 
infected by HIV and are thought o play an important role 
in the pathogenesis and progression of HIV-related isease 
[30-32]. Large numbers of infected macrophages have 
been found in lymph nodes, liver, spleen, lungs, skin, 
brain, and nearly all tissues and organs from infected 
subjects [31-33], and chronically infected macrophages are 
considered to be a reservoir for HIV in infected individu- 
als. Inhibition of virus production in such cells would 
require agents that are effective in inhibiting HIV gene 
expression or maturation, or in cleaving viral RNA se- 
quences. These agents may have limited access to the 
cytoplasm, and cationic liposomes may be useful for the 
delivery of antisense oligodeoxynucleotides, ribozymes or 
therapeutic genes into chronically infected macrophages. 
As a first step towards the use of such liposomes in 
macrophages, we investigated the toxicity of three cationic 
liposomal preparations, Lipofectamine, Lipofectin and li- 
posomes composed of DMRIE and DOPE (1 : 1), to human 
monocyte-derived macrophages and a differentiated mono- 
cytic cell line, THP-1. Since the cationic liposomes would 
eventually be used to deliver antiviral agents to HIV-in- 
fected cells, we also investigated the toxicity of the lipo- 
somes to macrophages infected with the monocytotropic 
strain HIV-IBa L, as well as to chronically infected THP- 
1/HIV-1Hm cells. Our results indicate that cationic lipo- 
somes have a differential toxicity for HIV-infected cells 
under certain conditions. Some of our results have been 
presented earlier in preliminary form [35]. 
2. Materials and methods 
2.1. Materials 
Lipofectamine Reagent [36] containing the polycationic 
lipid 2,3-dioleyloxy-N[2(sperminecarboxamido)ethyl]- 
N,N-dimethyl-l-propanaminium trifluoroacetate (DOSPA) 
and the neutral lipid, dioleoylphosphatidylethanolamine 
(DOPE) (3:1, w/w), and Lipofectin Reagent [3] containing 
the monocationic lipid N-[1-(2,3 dioleyloxy)-propyl]- 
N,N,N-trimethylammonium chloride (DOTMA) and DOPE 
(1:1, w/w) were obtained from Gibco BRL Life Tech- 
nologies, Inc. (Gaithersburg, MD). DMRIE reagent [37] (a 
1:1 (w/w)  mixture of 1,2-dimyristyloxypropyl-3- 
dimethyl-hydroxyethylammonium bro ide (DMRIE) and 
DOPE) was synthesized by VICAL, Inc. (San Diego, CA). 
Alamar Blue dye was purchased from Alamar Biosciences 
Inc. (Sacramento, CA). The enzyme-free, PBS-based, cell 
dissociation buffer was obtained from Gibco BRL Life 
Technologies, Inc. (Gaithersburg, MD). Triton X-100, 
Nonidet P-40 (NP-40) and naphtol blue black (Buffalo 
Black NBR), were obtained from Sigma (St. Louis, MO). 
2.2. Cells and virus 
Monocytes were obtained from HIV seronegative buffy 
coats by centrifugation on a Ficoll-Hypaque (Histopaque- 
1077; Sigma, St. Louis, MO) gradient and plastic adher- 
ence. Briefly, mononuclear cells separated by centrifuga- 
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tion were counted and plated in Dulbecco's Modified 
Eagle's Medium-high glucose (DME-HG) (Irvine Scien- 
tific, Santa Ana, CA) without serum, at 1.4. 106/ml per 
well or 5.6- 105/0.2 ml per well in 48-well or 96-well 
plates, respectively. It was assumed that approximately 
5-10% of the cells plated would be recovered as 
macrophages. The cells were allowed to adhere overnight, 
after which the wells were washed and the medium was 
replaced with DME-HG supplemented with 20% (v/v)  
heat-inactivated fetal bovine serum (FBS) (Sigma, St. 
Louis, MO), 10% (v/v)  human AB serum (Advanced 
Biotechnologies, Columbia, MD), penicillin (100 U/ml), 
streptomycin (100 ~zg/ml) and L-glutamine (4 mM). The 
cells were left undisturbed in this medium for 5-6 days, by 
which time differentiation occurred. Macrophages were 
then maintained at 37°C, under 5% CO 2 in DME/20 
(DME-HG + 20% heat-inactivated FBS) medium supple- 
mented with penicillin (100 U/ml), streptomycin (100 
txg/ml) and L-glutamine (4 mM). Every 2 days the medium 
was removed completely and replaced with fresh medium. 
Infection of macrophages was performed 8 days post- 
isolation. The virus and infected cells were handled in a 
BL-3 facility. A monocytotropic strain of HIV-I, recov- 
ered from primary lung cultures and designated HIV-1BaL 
[30], was used in these experiments. Cells were exposed to 
the virus for 2 h at 37°C; then the medium was removed 
and the cells were washed three times to remove unbound 
virus. After infection macrophages were cultured for an 
additional 12 days in fresh DME/20 medium, l ml/well 
or 0.25 ml/well in 48-well or 96-well plates, respectively, 
with medium changes 3 times/wk. The progress of infec- 
tion was monitored by determining viral p24 in culture 
supernatants, by an antigen capture ELISA assay described 
previously [38], using a Molecular Devices (Menlo Park, 
CA) Vma x microplate reader. 
Viral inocula were standardized by their p24 content, 
and cultures were infected at a concentration f 5 or 1.4 ng 
p24 per well in 48-well or 96-well plates, respectively. 
HIV-1Ba L obtained from Advanced Biotechnologies Inc. 
(Columbia, MD) was propagated in macrophages, har- 
vested at times of peak p24 production and stored in 1 ml 
aliquots at - 80°C. The reverse transcriptase activity of the 
virus stock solution was 8.3. 10 3 cpm/ml, and the p24 
concentration was 50 ng/ml. 
THP-1 cells were obtained from the American Type 
Culture Collection (TIB-202). A chronically HIV-infected 
cell line (designated THP-I/HIV-1 nIB) was developed in 
our laboratory by infecting THP-1 cells with HIV-I nm at a 
low multiplicity of infection [39]. THP-1/HIV-lmB cells 
were cloned by limiting dilution in flat-bottom 96-well 
plates. After 50 and 71 days in culture, supernatants were 
screened for HIV production, and it was found that 29 of 
30 clones obtained (96.7%) were positive for p24 produc- 
tion. Subsequently, samples of all clones were treated with 
160 nM phorbol 12-myristate 13-acetate (PMA), for 24 h 
at 37°C, to check for differentiation. Fifteen of the clones 
adhered strongly after PMA treatment and produced virus. 
These clones were expanded and cryopreserved. The clone 
designated as THP-1/ina30 was used in further experi- 
ments. Cells were maintained at 37°C, under 5% CO 2 in 
RPMI 1640 medium supplemented with 10% (v/v)  heat- 
inactivated FBS (RPMI/10), penicillin (100 U/ml), 
streptomycin (100 I~g/ml) and L-glutamine (2 raM). The 
cells were passaged 1:6 once a week. 
2.3. Exposure of cells to cationic liposomes 
HIV-1BaL-infected macrophages were treated with lipo- 
somes in the presence of 20% FBS, on day 12 post-infec- 
tion. Uninfected macrophages were treated with liposomes 
on day 11 post-isolation. Uninfected monocytic THP-1 
cells and chronically infected THP-1/HIV-IlI m cells (1 ml 
at l • l0  6 cells/ml) were plated in 48-well plates, treated 
with 160 nM PMA for 24 h at 37°C and exposed to 
liposomes in the presence of 10% FBS, 6 or 7 days 
post-differentiation. I fection of THP-1/HIV-1 mB cells 
was monitored by the p24 level in supernatants, p24 values 
represent the amount of virus produced (in ng/ml) be- 
tween the time of medium change and time of sampling 
for p24. This time period is indicated in the Figure legends 
for each experiment. 
The cells were exposed to Lipofectamine at3 or 8 IxM, 
and to Lipofectin and DMRIE at 15 or 40 IxM, for 4 h or 
24 h at 37°C; the medium with liposomes was then re- 
moved and fresh medium was added. Lipofectamine, the 
formulation containing the lipid DOSPA (carrying a sper- 
mine headgroup) with a charge of + 5 at neutral pH, was 
used at concentrations recommended bythe manufacturer's 
protocol (Lipofectamine at25 p,1/ml is equivalent to 12.5 
p,M lipid). The monocationic liposomal preparations, 
Lipofectin and DMRIE, were used at concentrations of 15 
p,M, which is equivalent o the highest recommended 
concentration (Lipofectin and DMRIE at 20 ixl/ml are 
equivalent to 13.7 p,M and 15 IxM lipid, respectively), and 
40 p~M, to obtain a higher positive charge concentration, 
slightly less than that of 3 o,M Lipofectamine. To achieve 
the number of positive charges equivalent to that for 8 )xM 
Lipofectamine, both Lipofectin and DMRIE would have to 
be used at concentrations of 120 IxM (~ 170 Ixl/ml), 
which is above the toxic level. Following treatment with 
liposomes, cells were cultured and fed every 2-3 days 
with fresh medium (DME/20 for macrophages and 
RPMI/10 for THP-1 cells). Control cells were treated 
similarly with the equivalent amount of appropriate medium 
but not exposed to liposomes. Liposome-related toxicity 
was evaluated by the Alamar Blue assay and p24 produc- 
tion. 
2.4. Cell viability assays 
Cell morphology before and after treatment with lipo- 
somes was evaluated by inverted phase contrast mi- 
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croscopy at 25 × magnification. The number of viable 
cells in suspension used for experiments was determined 
by Trypan Blue exclusion. 
Both macrophages and differentiated THP-1 cells that 
do not multiply after PMA-treatment adhere to the plastic, 
and accurate counting of adherent cells is difficult. Direct 
counting is often unsatisfactory, since it is difficult to 
select ruly representative microscopic fields. To overcome 
this problem we quantified cell viability after treatment 
with liposomes using a modified Alamar Blue assay [40]. 
The Alamar Blue assay was recently introduced by Alamar 
Biosciences (Sacramento, CA) as an indicator of cell via- 
bility allowing continuous monitoring of cell proliferation 
and/or cytotoxicity [40]. This colorimetric assay measures 
the oxido-reductive capacity of cells due to the production 
of metabolites, as a result of cell growth, and permits 
determination of viability over the culture period without 
the detachment of adherent cells. The non-toxic Alamar 
Blue dye can be washed off and the culture continued 
without ermination of the experiment. This assay has been 
applied to determine the proliferation of lymphocytes [41], 
and the adhesion rate and viability of monocytes and 
macrophages [42]. Briefly, 1.0 ml of appropriate medium 
and 0.1 ml of Alamar Blue, or 0.2 ml of medium and 20 
ILl of Alamar Blue, was added to 48-well or 96-well 
culture plates, respectively. After incubation for various 
times (described under Figure legends) at 37°C, 200 p,1 of 
the supernatant was collected from each well and trans- 
ferred to 96-well plates. The absorbance at 570 nm and 
600 nm was measured using a Molecular Devices Vn~ x 
microplate reader. Cell viability (as a percentage of mock- 
treated control cells) was calculated according to the for- 
mula, (A570 - -  A600) of test cells × 100/(A570 - -  At00) of 
control cells. After removal of the Alamar Blue/medium 
mixture, fresh growth medium was added and the cells 
were returned to the incubator. 
The results obtained by the Alamar Blue assay were 
correlated with two indirect methods: Trypan Blue exclu- 
sion and nuclear counting [43]. Adherent cells were de- 
tached, using the enzyme-free dissociation buffer, and 
counted by the Trypan Blue exclusion method. For nuclear 
staining, adherent cells were washed with PBS and treated 
with 0.1 ml of the counting solution, I% (w/v)  Triton 
X-100 in 0.1 M citric acid with 0.05% (w/v)  naphtol blue 
black, pH 2.2. After 30 min incubation at room tempera- 
ture the solution was mixed and the suspension of fixed 
stained nuclei was counted in a hemocytometer. 
3. Results 
3.1. Effect of liposomes on uninfected macrophages 
Uninfected macrophages were treated with the cationic 
liposomes for 24 h, and cell viability was quantified by the 
Alamar Blue assay on days 7, 9, 11 and 15 after treatment. 
Lipofectamine and Lipofectin were not toxic at the concen- 
tration range tested. The toxic effect of DMRIE was very 
limited, and a decrease in cell viability by ~ 20% could be 
observed after 15 days (Fig. 1). A 4 h treatment of 
uninfected macrophages with the cationic liposomes was 
not toxic, even up to 15 days post-treatment (data not 
shown). 
3.2. Effect of liposomes on chronically infected 
macrophages 
Chronic HIV-1 infection is usually established in in- 
fected macrophages 10-12 days after virus challenge, as 
determined by stabilization of both the number of HIV 
antigen-expressing cells detected by immunofluorescence 
and proviral DNA determined by the polymerase chain 
reaction [44]. We treated HIV-1B~L-infected macrophages 
with the cationic liposomes on day 12 post-infection, when 
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Fig. 1. Effect of cationic liposomes on viability of uninfected macrophages. Macrophages in 96-well plates were xposed tothe cationic liposomes (LipA: 
Lipofectamine. Lipof: Lipofectin) for 24 h, 11 days post-isolation, as described in Section 2. Cell viability was measured bythe Alamar Blue assay on days 
7, 9, 11 and 15 (incubation for 2.5-4 h at 37°C) and was expressed aspercent of the control. Data represent the mean +__ SD obtained from duplicate wells. 
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chronic infection was already established. Infection of 
macrophages reduced cell viability by about 50% (data not 
shown). We also determined p24 production in chronically 
infected macrophages before treatment with the cationic 
liposomes. Only wells exhibiting similar cell viability and 
p24 production were exposed to the cationic liposomes; 
this procedure allowed us to avoid inter-experiment vari- 
ability caused by differences both in initial infection and 
its progression. 
HIV-1BaL-infected macrophages were treated with the 
cationic liposomes for 4 h; cell viability was quantified on 
days 6 and 13, and p24 production was measured on days 
7 and 14 after treatment. After a 24 h treatment, cell 
viability and p24 production were determined on days 6 
and 14 after treatment. Neither Lipofectamine nor Lipo- 
fectin was toxic after a 4 h treatment, while a decrease in 
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Fig. 2. Effect of cationic liposomes on viability of HIV-1BaL-infected 
macrophages. (A) Macrophages in 48-well plates, were exposed to the 
cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 4 h as 
described in Section 2. Cell viability was measured by the Alamar Blue 
assay on days 6 and 13 (incubation for 2.5-4 h at 37°C) and was 
expressed as percent of the control. (B) Macrophages in 96-well plates 
were exposed to the cationic liposomes for 24 h. Cell viability was 
measured on days 6 and 14 (incubation for 2.5 h or overnight at 37°C) 
and was expressed as percent of the control. Data represent the mean + SD 
obtained from triplicate wells or 6-8 control wells. 
Fig. 3. Effect of cationic liposomes on p24 production in HIV-IB~L-in- 
fected macrophages. (A) Macrophages in 48-well plates were exposed to 
the cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 4 h 
as described in Section 2. The p24 antigen production within a 24 h 
period was determined in cell culture supernatants ondays 6 and 13 after 
treatment and was expressed as percent of the control (100%: 20.9_+ 1.8 
and 9.1 _+ 1.8 ng p24/ml on days 6 and 13, respectively). Data represent 
the mean _+ standard deviation of p24 determinations in duplicate, in 
supernatants of triplicate wells (n = 6) or 6 control wells (n = 12). (B) 
Macrophages in 96-well plates were exposed to the cationic liposomes for 
24 h. A 48-h production of p24 antigen was determined in cell culture 
supernatants on days 6 and 14 after treatment and was expressed as 
percent of the control (100%: 101.0_+ 13.6 and 20.1 _+3.6 ng p24/ml on 
days 6 and 14, respectively). Data represent the mean+SD of p24 
determination i  duplicate, in supernatants of triplicate wells (n = 6) or 8 
control wells (n = 16). 
40 ~M (Fig. 2A). A 24 h exposure to Lipofectin at 15 or 
40 IxM reduced cell viability by ~ 20% and 30%, respec- 
tively (Fig. 2B). At the same concentrations, DMRIE 
caused greater cytotoxicity, reducing cell viability by ~ 
40% and 70% at 15 and 40 ~M, respectively. Lipofec- 
tamine was not toxic after a 24 h treatment. Similar results 
were obtained when the effects of cationic liposomes were 
determined by measuring p24 levels in the harvested su- 
pernatant (Fig. 3). However, there were some differences 
between the viability assay and p24 production. For exam- 
ple, while no detectable cytotoxicity was observed at 15 
ixM DMRIE after a 4 h treatment (Fig. 2A), the production 
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of p24 antigen in the culture supernatant was inhibited by 
~ 30% (Fig. 3A) 
3.3. Effect of liposomes on differentiated uninfected THP-1 
cells 
PMA-treated THP-1 cells were exposed to the cationic 
liposomes for 24 h, and cell viability was quantified on 
days 6, 9, and 13 after treatment (Fig. 4). While Lipofec- 
tamine at 3 and 8 txM and Lipofectin at 15 IxM were not 
toxic, 40 IxM Lipofectin caused a reduction in cell viabil- 
ity by ~40% on days 6 and 9, and by 70% on day 13. 
Although the toxic effect of DMRIE was limited, a de- 
crease in cell viability by 30-40% could be observed after 
13 days at both concentrations (Fig. 4), 
3.4. Effect of liposomes on differentiated THP-1/ HIV-lm8 
cells 
Differentiated THP- 1/HIV- 1111B cells were treated with 
the cationic liposomes for 4 h; cell viability was quantified 
on days 5 and 14, and p24 production was measured on 
days 5, 8 and 14 after treatment. A 4 h exposure to any of 
the three liposomes did not reduce cell viability and p24 
production even up to 14 days post-treatment (data not 
shown). Following a 24 h treatment of these cells, cell 
viability was determined on day 1, 8 and 12, and p24 
production was measured on days 3, 7 and 12 after the end 
of the treatment period. At the lower concentration, one 
of the three liposomes reduced cell viability after a 24 h 
treatment as measured by the Alamar Blue assay (Fig. 5A). 
However, Lipofectin and DMRIE at 15 ~M inhibited viral 
p24 production measured on days 7 and 12 after treatment 
by ~ 40% (Fig. 5B), although they did not show an effect 
on day 3. All three cationic liposomes were toxic at the 
higher concentration after a 24 h treatment (Fig. 5A,B). 
Interestingly, concentrations of liposomes that were not 
toxic at early time points subsequent to treatment could 
cause significant toxicity at later times. For example, p24 
production was not affected by 40 p,M Lipofectin or 
DMRIE on day 3, while on days 7 and 12 it was reduced 
by ~ 80% (Fig. 5B). 
3.5. Comparison of the Alamar Blue assay with the Trypan 
Blue exclusion and the nuclear counting methods 
PMA-treated THP- 1 and THP- 1/HIV- 1 nm cells were 
exposed to the cationic liposomes for 24 h. On day 9 after 
treatment, he Alamar Blue assay was performed, and cell 
numbers were detemined by counting. DMRIE at 15 and 
40 p~M was not toxic for differentiated uninfected THP-1 
cells, while a 24 h exposure to Lipofectin at 40 ixM 
reduced cell viability by ~ 50% (Fig. 6A). Lipofectin at 
40 p~M and DMRIE at 15 and 40 IxM reduced the viability 
of differentiated THP-1/HIV-1In B cells by ~ 50%, 60% 
and 90%, respectively (Fig. 6B). After removal of the 
Alamar Blue/medium ixture the cells were quantified by 
the Trypan Blue assay and the nuclear staining method. In 
the Trypan Blue assay only live cells were counted be- 
cause the affected cells were disintegrating to such an 
extent hat very few cells took up and retained the Trypan 
Blue. The results were consistent with phase contrast 
microscopic observations (described below) that the cyto- 
toxic effect was caused by significant damage of the cells 
and not by mere changes in cell membrane permeability. 
The viability of control mock-treated cells was 91-96%; 
however, the absolute number of cells was only 10% of the 
initially plated 106 cells/well. Thus, during the course of 
the experiment, approximately 90% of cells were detached 
and lost. The number of viable cells quantified in the 
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Fig. 4. Effect of cationic liposomes on viability of differentiated uninfected THP-I cells. PMA-treated THP-I cells in 48-well plates were exposed to the 
cationic liposomes (LipA: Lipofectamine. Lipof: Lipofectin) for 24 h, 7 days post-differentiation, as described in Section 2. Cell viability was measured on 
days 6, 9, and 13 (incubation overnight at 37°C) and was expressed as percent of the control. Data represent the mean + SD obtained from duplicate wells 
or triplicate control wells. 
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Trypan Blue assay corresponded very well to the number 
of nuclei stained with the naphtol blue black dye. For 
example, the number of viable THP-1/HIV-1Hm cells and 
their nuclei, counted in duplicate control wells with the 
Trypan Blue or naphtol blue black methods, was 1.24 ___ 
0.07 • 105 and 1.07 ___ 0.03 • 105, respectively. 
When expressed as a percentage of controls, both the 
Trypan Blue exclusion and the nuclear counting methods 
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Fig. 5. Effect of cationic liposomes on viability and p24 production in 
differentiated THP- I /HIV- lnm cells. PMA-treated THP-1/HIV- lma 
cells in 48-well plates were exposed to the cationic liposomes (LipA: 
Lipofectamine. Lipof: Lipofectin) for 24 h, 6 days post-differentiation, as 
described in Section 2. (A) Cell viability was measured on days 1, 8, and 
12 (incubation overnight with Alamar Blue at 37°C) and was expressed as 
percent of the control. Data represent he mean+standard deviation 
obtained from duplicate wells or triplicate control wells. (B) The p24 
antigen production within the previous 48 h period was determined in cell 
culture supernatants on days 3 and 7; on day 12, p24 production within 
the previous 72 h was measured. The values were expressed as percent of 
the control (100%: 7.9+0.9, 15.1___2.5 and 13.1-1-1.4 ng p24/ml on 
days 3, 7 and 12, respectively). Data represent he mean+standard 
deviation of p24 determination i  duplicate, in supernatants of duplicate 
wells (n = 4) or triplicate control wells (n = 6). 
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Fig. 6. Effect of cationic liposomes on the viability of differentiated 
THP-1 and THP-1/HIV-Ium cells-comparison f the Alamar Blue assay 
with Trypan Blue exclusion and the nuclear counting methods. PMA- 
treated THP-1 and THP-1/HIV-11nB cells in 48-well plates were exposed 
to the cationic liposomes (Lipof: Lipofectin) for 24 h, 6 days post-differ- 
entiation, as described in Section 2 (4 wells/condition). On day 9 
post-treatment, cell viability was measured by the Alamar Blue assay 
(incubation for 3 h and 20 min at 37°C) and was expressed as percent of 
the control. After removal of the Alamar Blue/medium mixture, the 
number of viable cells or their nuclei were counted with the Trypan Blue 
or naphtol blue black methods, respectively, and expressed as the percent- 
age of the control. Data represent the mean + SD obtained from quad- 
ruplicate wells (Alamar Blue) or duplicate wells (Trypan Blue or naphtol 
blue black). (A) THP-1 cells; Alamar Blue assay, 100%: A570 - A600 = 
0.39; Trypan Blue assay, 100%: 1.04-105 cells; naphtol blue black, 
100%: 1.02.105 cells. (B) THP-1/HIV-lmB cells; Alamar Blue assay, 
100%: A570 - A600 = 0.334; Trypan Blue assay, 100%: 1.24.105 cells; 
naphtol blue black, 100%: 1.07.105 cells. 
gave results similar to that obtained with the Alamar Blue 
assay (Fig. 6A and B). Variation in the results was found 
only in the case of THP-1/HIV-lnI B cells treated with 40 
IxM DMRIE, where a very significant cytotoxic effect was 
observed. The trend in the toxic effect of the cationic 
liposomes was similar to that presented in Figs. 4 and 5A, 
although some inter-experiment variations were observed. 
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Fig. 7. Effect of cationic liposomes on the morphology of differentiated uninfected THP-1 cells. PMA-treated THP-1 cells in 48-well plates were exposed 
to the cationic liposomes for 24 h, 7 days post-differentiation, as described in Section 2. Phase contrast micrographs were taken 3 days after treatment 
(magnification: 400 × ). Frame a shows untreated cells. Frames b - f  show cells treated with 8 I.LM Lipofectamine (b), 15 ~M Lipofectin (c), 40 ixM 
Lipofectin, 15 $xM DMRIE (e), and 40 p,M DMRIE (f). 
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3.6. Cell morpho logy 
Cell morphology can be a sensitive indicator of the 
toxicity of certain compounds. PMA-treated THP-1 cells 
were exposed to the cationic liposomes for 24 h, and 
micrographs were taken 3 days after treatment in the same 
experiment whose results are shown in Fig. 4. Lipofec- 
tamine, at the concentrations u ed in our studies, had no 
significant effect on the morphology of differentiated 
THP-1 cells compared to untreated control cells (Fig. 7b). 
40 p~M Lipofectin was highly cytotoxic, causing disinte- 
gration of cells (Fig. 7d). Changes of cell morphology 
were also seen with 40 ixM DMRIE (Fig. 70. 
4. Discussion 
In this study, we investigated the toxicity of one polyca- 
tionic (Lipofectamine) and two monocationic (Lipofectin 
and DMRIE) liposomal preparations to uninfected and 
HIV-infected cells. Our results demonstrate that (i) 
macrophages and PMA-treated THP- 1 or THP- 1/HIV- 1 nlB 
cells differ in their sensitivity to the toxic effect of cationic 
liposomes; (ii) HIV-infected cells are more susceptible to 
killing by cationic liposomes than uninfected cells; (iii) 
concentrations of liposomes that were not toxic at early 
time points subsequent to treatment could cause toxicity at 
later times; (iv) in infected cells, virus production is more 
sensitive to the effects of cationic liposomes than the 
overall viability of the cells as measured by a metabolic 
assay. 
Chronically HIV-1-infected macrophages and differenti- 
ated THP-1/HIV-lnm cells were selected in our study 
because of the importance of macrophages in the patho- 
genesis and progression of HIV infection [32,33]. The avid 
endocytosis of liposomes by mononuclear phagocytes [45- 
47] should promote cationic lipid-mediated transfection of 
therapeutic genes and delivery of anti-HIV anti-sense 
oligodeoxyribonucleotides or ribozymes via the endocy- 
totic pathway. 
Both cationic lipids alone and lipid-DNA complexes 
show various levels of growth inhibition and toxicity to 
cells, depending on the cell type and the confluency of the 
cell culture [3,8,22,48-50]. The molecular and cellular 
basis of this variability is not known. Generally, trans- 
fected cells are temporarily growth-arrested or grow more 
slowly than untransfected cells [51]. In our study, 
macrophages and differentiated THP-1 cells were exposed 
to liposomes in the presence of 20% or 10% FBS, respec- 
tively. Although earlier reports on lipofection emphasized 
the use of serum-free conditions, recent studies indicate 
that successful transfections with cationic liposomes can 
be achieved in the presence of serum, provided that the 
lipid-DNA complexes are prepared under serum-free con- 
ditions. The presence of serum can also diminish the 
growth inhibition and/or toxic effects associated with 
lipofection [52,53]. 
Two questions raised by our findings are (i) why differ- 
entiated THP-1 and THP-I/HIV-1 mB cells were more 
sensitive than macrophages to the toxic effect of cationic 
liposomes, and (ii) why THP-1 cells were more sensitive 
to Lipofectin (Fig. 4), while DMRIE was more toxic to 
macrophages (Fig. 2). The established human monocytoid 
cell lines have been used to study HIV-monocyte/macro- 
phage interactions, the relationship between virus produc- 
tion and cell differentiation, and virus latency [54-56]. 
Compared to other monocytoid cell lines, differentiated 
THP-1 cells behave more like native monocyte-derived 
macrophages [57]. More than 80% of the PMA-treated 
THP-1 cells change morphologically and adhere to the 
substratum; 60 to 70% of these cells are able to phagocy- 
tose yeast particles and immunoglobulin G-coated erythro- 
cytes [58]. PMA-treated THP- 1/HIV- lttm cells represent a 
convenient model of HIV-1 production in differentiated 
cells [39]. The monocytoid cells are a useful tool for 
studying specific aspects of virus-cell interactions; how- 
ever, none of these cell lines properly represents mono- 
cyte/macrophages. The capacity of HIV-1 isolates to 
replicate in established monocytoid cell lines does not 
correlate with the tropism of the virus for primary 
mononuclear phagocytes [56,59]. HIV-1BaL does not repli- 
cate in any of the monocytoid cell lines in spite of high 
CD4 expression i  some of the lines, and both the expres- 
sion of cell surface markers and cytokine production vary 
significantly among these cell lines. For example, the 
monocytic marker CD14 is expressed in few THP-I cells 
(4%), but in a majority of blood monocytes (97%) [59]. 
Thus, the different sensitivity of macrophages and THP-I 
cells to cationic liposomes may be related to the differ- 
ences in the intrinsic properties of the cells. The structural 
characteristics of the different lipids may also determine 
how they interact with the different cell surface compo- 
nents on these two cell types. Interestingly, the formation 
of complexes between cationic liposomes and RNA signif- 
icantly changed the toxic effect of liposomes [60]. A 4-h 
treatment of differentiated THP-1 cells with the Lipofec- 
tamine/ribozyme complex at 8 p~M lipid caused a de- 
crease in cell viability by ~ 80% [60], while 8 IxM 
Lipofectamine alone was not toxic even after a 24-h 
treatment (Fig. 4). In contrast, a 24-h treatment with the 
Lipofectin/ribozyme complex at 40 lxM lipid was not 
toxic, while with 40 p~M Lipofectin alone cell viability 
was significantly reduced (Fig. 4). Incubation of endothe- 
lial cells for 4 h with 24 IxM (or greater) Lipofectin in the 
presence of antisense oligonucleotides in serum-free 
medium (followed by overnight incubation in serum-con- 
taining medium without the cationic lipids) was toxic to 
these cells, as determined by the loss of adherent cells at 
the end of this incubation period [29]. 
Another question raised by our results is why chroni- 
cally HIV-l-infected cells are killed more effectively by 
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cationic liposomes than are uninfected cells. The interac- 
tion of cationic liposomes with cells involves surface 
binding and internalization, and it is unclear which cellular 
component(s) are involved in these processes. The effects 
of HIV infection on monokine production and metabolic 
and immune functions of macrophages, both in vivo and in 
vitro, are not well defined [33,34]. It is possible that the 
continuous production (budding) of the virus and expres- 
sion of viral envelope proteins can alter the susceptibility 
of the cell membrane in HIV-infected cells to interaction 
with cationic liposomes. Our results indicate that cells with 
relatively high overall viability could be impaired in their 
ability to produce virions. Thus, virus production appears 
to be more sensitive to treatment with the cationic lipo- 
somes than cell viability measured by the Alamar Blue 
assay. This observation suggests that cationic liposomes, 
by inserting into intracellular membranes, may affect the 
transport of viral components o the cell surface and virus 
budding. Cytoplasmic vesicles in epithelial cells in which 
antisense oligonucleotide/Lipofectin complexes accumu- 
late appear to be larger than those in which the oligo- 
nucleotide alone accumulates [29]. One interpretation that 
has been offered for this observation is that the lipid 
promotes fusion of smaller cytoplasmic vesicles [29]. 
Our results indicate that cationic liposomes can have 
prolonged effects on cells after the initial incubation pe- 
riod. Although cationic liposomes may appear to have no 
cytotoxicity within a few days after treatment, hey may 
become toxic later. It is therefore important o monitor 
cytotoxicity for relatively long time periods. This delayed 
cytotoxicity may be related to the stability of the cationic 
lipids used in this study, and the inability of the cells to 
metabolize them. In this respect it will be of interest o 
compare the toxic effect of these lipids which contain ether 
bonded alkyl chains to liposomes containing (N[1-(2,3-di- 
oleoyloxy)propyl]-N,N,N-trimethylammonium ethylsul- 
fate (DOTAP), which has ester bonded acyl chains [20,22]. 
It is interesting to note that Lipofectamine is less toxic 
than Lipofectin in the cellular systems tested, even at 
higher concentrations of the cationic lipid component and 
a higher number of charges per DOSPA molecule. For 
example, 8 p~M Lipofectamine reagent corresponds to 24 
p~M DOSPA, equivalent to 120 I~M in cations, while 15 
~M Lipofectin corresponds to 15 IxM DOTMA, equiva- 
lent to the same concentration f cations. This observation 
indicates that the concentration f positive charge per se is 
not a determinant of toxicity. Cytotoxicity is more likely to 
be linked to the structure of the cationic molecule as well 
as its ability to be metabolized by the cell. 
Our observations point to the importance of evaluating 
lipid-dependent effects on virus replication when the thera- 
peutic effects of antisense oligonucleotides, ribozymes or 
genes delivered by cationic liposomes are being investi- 
gated. Although this study has concentrated on the toxic 
effects of pure lipids, the toxicity of nucleic acid/cationic 
liposome complexes needs to be examined just as thor- 
oughly when evaluating the sequence-dependent effects of 
therapeutic nucleic acids on virus production or cell prolif- 
eration. 
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